Lista de obras -

A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors

artículo científico publicado en 2015

A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease ⬇️

artículo científico publicado el 9 de mayo de 2013

A Rapid Method to Regenerate Piezoelectric Microcantilever Sensors (PEMS) ⬇️

artículo científico publicado el 1 de enero de 2011

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

artículo científico publicado en 2009

Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer

artículo científico publicado en 2017

Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial

artículo científico publicado en 2014

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

artículo científico publicado en 2016

Bilateral granulosa cell tumors: a novel malignant manifestation of multiple endocrine neoplasia 1 syndrome found in a patient with a rare menin in-frame deletion

artículo científico publicado en 2015

Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)

scientific article published on 06 November 2019

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

artículo científico publicado en 2016

Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer.

artículo científico publicado en 2019

Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer

artículo científico publicado en 2009

Cutaneous precursor B-cell lymphoblastic lymphoma in 2 adult patients: clinicopathologic and molecular cytogenetic studies with a review of the literature.

artículo científico publicado en 2008

Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma.

artículo científico publicado en 2004

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

artículo científico publicado en 2017

First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors

artículo científico publicado en 2017

Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?

artículo científico

Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors

artículo científico publicado en 2017

Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group

scientific article published on 01 May 2007

Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma

artículo científico publicado en 2016

Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma.

artículo científico publicado en 2013

Mesothelin, a novel immunotherapy target for triple negative breast cancer ⬇️

artículo científico publicado el 15 de marzo de 2012

Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.

artículo científico publicado en 2016

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

artículo científico publicado en 2016

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

artículo científico publicado en 2016

Naptumomab estafenatox: a new immunoconjugate

scientific article published on February 2010

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2016

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

artículo científico publicado en 2017

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2016

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

artículo científico publicado en 2016

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

artículo científico publicado en 2015

Non-Small Cell Lung Cancer, Version 6.2015.

artículo científico publicado en 2015

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials

scientific article published on 11 September 2020

Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer

artículo científico

Personalized medicine and treatment approaches in non-small-cell lung carcinoma ⬇️

artículo científico publicado el 25 de septiembre de 2012

Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.

artículo científico publicado en 2017

Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.

artículo científico publicado en 2014

Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer

artículo científico publicado en 2009

Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma

artículo científico publicado en 2004

Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.

artículo científico publicado en 2008

Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy

artículo científico publicado en 2008

Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature

artículo científico publicado en 2005

Rational use of cetuximab in the treatment of advanced non-small cell lung cancer.

artículo científico publicado en 2009

Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

artículo científico publicado en 2004

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease

artículo científico publicado en 2010

Targeted therapies in solid tumors: monoclonal antibodies and small molecules

artículo científico publicado en 2006

Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations

artículo científico publicado en 2020

The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types

scientific article published on 13 May 2020

The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement

artículo científico publicado en 2012

Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer

artículo científico publicado en 2009

Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design

artículo científico publicado en 2017

Lista de obras de

A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors

A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease ⬇️

A Rapid Method to Regenerate Piezoelectric Microcantilever Sensors (PEMS) ⬇️

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer

Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Bilateral granulosa cell tumors: a novel malignant manifestation of multiple endocrine neoplasia 1 syndrome found in a patient with a rare menin in-frame deletion

Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer.

Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer

Cutaneous precursor B-cell lymphoblastic lymphoma in 2 adult patients: clinicopathologic and molecular cytogenetic studies with a review of the literature.

Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma.

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors

Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?

Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors

Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group

Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma

Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma.

Mesothelin, a novel immunotherapy target for triple negative breast cancer ⬇️

Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

Naptumomab estafenatox: a new immunoconjugate

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Non-Small Cell Lung Cancer, Version 6.2015.

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials

Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer

Personalized medicine and treatment approaches in non-small-cell lung carcinoma ⬇️

Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.

Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.

Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer

Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma

Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.

Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy

Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature

Rational use of cetuximab in the treatment of advanced non-small cell lung cancer.

Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease

Targeted therapies in solid tumors: monoclonal antibodies and small molecules

Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations

The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types

The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement

Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer

Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design